0 XP   0   0   0

PhaseBio Pharmaceuticals Inc










Financial Health of Phasebio




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Richest
#1179 / 1193

Total Sales
#1187 / 1193

Making Money
#100 / 1193

Working Efficiently
#1081 / 1193

PhaseBio Pharmaceuticals Inc
Buy, Hold or Sell?

Should you buy, hold or sell Phasebio?

I guess you are interested in PhaseBio Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Phasebio

Let's start. I'm going to help you getting a better view of PhaseBio Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is PhaseBio Pharmaceuticals Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how PhaseBio Pharmaceuticals Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value PhaseBio Pharmaceuticals Inc. The closing price on 2022-11-25 was $0.059 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
PhaseBio Pharmaceuticals Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

1.1. Profitability of PhaseBio Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Phasebio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • A Net Profit Margin of -8,012.0% means that $-80.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is -8,012.0%. The company is making a huge loss. -2
  • The TTM is -6,971.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,012.0%TTM-6,971.9%-1,040.1%
TTM-6,971.9%YOY-69.4%-6,902.5%
TTM-6,971.9%5Y-2,264.0%-4,707.9%
5Y-2,264.0%10Y-2,156.1%-107.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,012.0%-223.6%-7,788.4%
TTM-6,971.9%-281.7%-6,690.2%
YOY-69.4%-344.8%+275.4%
5Y-2,264.0%-450.1%-1,813.9%
10Y-2,156.1%-541.0%-1,615.1%
1.1.2. Return on Assets

Shows how efficient Phasebio is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • -75.2% Return on Assets means that Phasebio generated $-0.75 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is -75.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.0%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-75.2%TTM0.0%-75.2%
TTM0.0%YOY-39.8%+39.8%
TTM0.0%5Y-20.4%+20.4%
5Y-20.4%10Y-30.1%+9.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-75.2%-9.9%-65.3%
TTM0.0%-8.9%+8.9%
YOY-39.8%-9.3%-30.5%
5Y-20.4%-11.7%-8.7%
10Y-30.1%-12.7%-17.4%
1.1.3. Return on Equity

Shows how efficient Phasebio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • 0.0% Return on Equity means Phasebio generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-225.7%+225.7%
TTM-5Y-57.1%+57.1%
5Y-57.1%10Y-72.8%+15.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--12.0%+12.0%
TTM--11.5%+11.5%
YOY-225.7%-10.8%-214.9%
5Y-57.1%-14.2%-42.9%
10Y-72.8%-15.2%-57.6%

1.2. Operating Efficiency of PhaseBio Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Phasebio is operating .

  • Measures how much profit Phasebio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • An Operating Margin of -7,956.3% means the company generated $-79.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is -7,956.3%. The company is operating very inefficient. -2
  • The TTM is -6,904.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-7,956.3%TTM-6,904.2%-1,052.0%
TTM-6,904.2%YOY-64.9%-6,839.3%
TTM-6,904.2%5Y-2,218.0%-4,686.2%
5Y-2,218.0%10Y-2,112.4%-105.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7,956.3%-207.3%-7,749.0%
TTM-6,904.2%-271.0%-6,633.2%
YOY-64.9%-325.9%+261.0%
5Y-2,218.0%-454.0%-1,764.0%
10Y-2,112.4%-537.1%-1,575.3%
1.2.2. Operating Ratio

Measures how efficient Phasebio is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 122.69 means that the operating costs are $122.69 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 122.692. The company is inefficient in keeping operating costs low. -1
  • The TTM is 93.460. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ122.692TTM93.460+29.233
TTM93.460YOY0.759+92.701
TTM93.4605Y32.298+61.162
5Y32.29810Y30.760+1.538
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ122.6922.871+119.821
TTM93.4603.504+89.956
YOY0.7593.604-2.845
5Y32.2985.132+27.166
10Y30.7606.371+24.389

1.3. Liquidity of PhaseBio Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Phasebio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.47 means the company has $0.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 0.469. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.632. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.469TTM1.632-1.164
TTM1.632YOY4.459-2.827
TTM1.6325Y5.807-4.175
5Y5.80710Y5.750+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4695.117-4.648
TTM1.6325.755-4.123
YOY4.4595.854-1.395
5Y5.8076.511-0.704
10Y5.7506.222-0.472
1.3.2. Quick Ratio

Measures if Phasebio is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • A Quick Ratio of 0.32 means the company can pay off $0.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 0.316. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.326. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.316TTM1.326-1.010
TTM1.326YOY3.771-2.445
TTM1.3265Y5.340-4.014
5Y5.34010Y5.086+0.254
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3164.284-3.968
TTM1.3264.664-3.338
YOY3.7714.787-1.016
5Y5.3405.218+0.122
10Y5.0865.182-0.096

1.4. Solvency of PhaseBio Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Phasebio assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Phasebio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 6.30 means that Phasebio assets are financed with 629.6% credit (debt) and the remaining percentage (100% - 629.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 6.296. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 3.532. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ6.296TTM3.532+2.764
TTM3.532YOY1.133+2.399
TTM3.5325Y1.906+1.626
5Y1.90610Y1.835+0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2960.278+6.018
TTM3.5320.277+3.255
YOY1.1330.306+0.827
5Y1.9060.367+1.539
10Y1.8350.403+1.432
1.4.2. Debt to Equity Ratio

Measures if Phasebio is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Phasebio to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY5.840-5.840
TTM-5Y1.362-1.362
5Y1.36210Y1.332+0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.315-0.315
TTM-0.317-0.317
YOY5.8400.319+5.521
5Y1.3620.403+0.959
10Y1.3320.462+0.870

2. Market Valuation of PhaseBio Pharmaceuticals Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Phasebio generates.

  • Above 15 is considered overpriced but always compare Phasebio to the Biotechnology industry mean.
  • A PE ratio of -1.80 means the investor is paying $-1.80 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The EOD is -0.177. Company is losing money. -2
  • The MRQ is -1.795. Company is losing money. -2
  • The TTM is -3.894. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-0.177MRQ-1.795+1.619
MRQ-1.795TTM-3.894+2.099
TTM-3.894YOY-6.312+2.418
TTM-3.8945Y-13.635+9.741
5Y-13.63510Y-12.986-0.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.177-8.986+8.809
MRQ-1.795-9.792+7.997
TTM-3.894-16.243+12.349
YOY-6.312-20.876+14.564
5Y-13.635-16.665+3.030
10Y-12.986-14.732+1.746
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Phasebio.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The MRQ is 5.415. Seems overpriced? -1
  • The TTM is 15.693. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ5.415TTM15.693-10.278
TTM15.693YOY14.222+1.471
TTM15.6935Y-287.711+303.404
5Y-287.71110Y-287.7110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.415-0.032+5.447
TTM15.6930.004+15.689
YOY14.2220.016+14.206
5Y-287.7110.006-287.717
10Y-287.7110.003-287.714

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Phasebio is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.25 means the investor is paying $-0.25 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of PhaseBio Pharmaceuticals Inc:

  • The EOD is -0.025. Bad. Book ratio is negative. -2
  • The MRQ is -0.255. Bad. Book ratio is negative. -2
  • The TTM is -1.344. Bad. Book ratio is negative. -2
Trends
Current periodCompared to+/- 
EOD-0.025MRQ-0.255+0.230
MRQ-0.255TTM-1.344+1.089
TTM-1.344YOY11.100-12.445
TTM-1.3445Y4.031-5.375
5Y4.03110Y3.839+0.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0251.835-1.860
MRQ-0.2552.006-2.261
TTM-1.3442.774-4.118
YOY11.1003.453+7.647
5Y4.0312.713+1.318
10Y3.8392.402+1.437
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of PhaseBio Pharmaceuticals Inc.

3.1. Institutions holding PhaseBio Pharmaceuticals Inc

Institutions are holding 55.205% of the shares of PhaseBio Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30NEA Management Company, LLC13.32520.2047664370200
2022-06-30Avidity Partners Management LP8.83510.0607440500000
2022-06-30Rock Springs Capital Management LP5.56550.048527748691610446.1612
2022-06-30Vanguard Group Inc3.626501808098-18033-0.9875
2022-06-30Mccormack Advisors International3.42790.0196170910429082520.5055
2022-06-30Johnson & Johnson3.22320.2463160704400
2022-06-30CHI Advisors LLC1.50430.17197500007500000
2022-06-30Stifel Financial Corp0.8810.000443926514726750.4342
2022-06-30Dafna Capital Management LLC0.75940.061937861100
2022-06-30Geode Capital Management, LLC0.6431032064200
2022-06-30Acadian Asset Management LLC0.54710.00082727702727700
2022-06-30New Legacy Group, LLC0.48250.29224057500
2022-09-30Platform Technology Partners0.46510.0234231900-11000-4.5286
2022-06-30Bridgeway Capital Management, LLC0.25390.0017126600-160000-55.8269
2022-06-30Marshall Wace Asset Management Ltd0.24680.0002123039-98444-44.4477
2022-06-30JANE STREET GROUP, LLC0.22601126681126680
2022-06-30Citadel Advisors Llc0.216501079531079530
2022-06-30State Street Corporation0.184209185040004.5532
2022-06-30SNOWDEN CAPITAL ADVISORS LLC0.12190.001660800900017.3745
2022-06-30Northern Trust Corp0.116605811900
Total 44.65181.133722262609+1568050+7.0%

3.2. Funds holding PhaseBio Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr2.31960115652600
2022-03-31Wellington CIF Biotechnology0.85570.7133426621-16206-3.6597
2022-09-30Fidelity® Extended Market Index0.33180.000116542200
2022-06-30Bridgeway Ultra-Small Company Market0.24070.0379120000-160000-57.1429
2022-06-30BlackRock Extended Mkt Composite0.16060.000480093800930
2022-09-30BlackRock Extended Equity Market K0.14180.000170717-651-0.9122
2022-09-30Fidelity® NASDAQ Composite Index®0.13870.00016913200
2022-10-31iShares Core S&P Total US Stock Mkt ETF0.094804725300
2022-09-30Fidelity® Series Total Market Index0.076403808600
2022-09-30NT Ext Equity Mkt Idx Fd - NL0.06660.00013318100
2022-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.05370.0001267563571.3523
2022-09-30Fidelity® Total Market Index0.053402663200
2022-09-30Northern Trust Extended Eq Market Idx0.04550.00012266900
2022-09-30NT Ext Equity Mkt Idx Fd - L0.04550.00012266900
2022-09-30Spartan Total Market Index Pool E0.032801634600
2022-09-30Vanguard U.S. Eq Idx £ Acc0.032401614600
2022-06-30BlackRock Advantage SMID Cap Instl0.02570.00241278900
2022-02-28The Vanguard Total Stock Market Index0.01760.0001877200
2022-03-31BlackRock Advantage SMID Cap V.I. Fd I0.0140.0053697100
2022-09-301290 VT Micro Cap K0.01290.0008644000
Total 4.76020.76092373221-96407-4.1%

3.3. Insider Transactions

Insiders are holding 6.721% of the shares of PhaseBio Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-10-25Enterprise Associates 13 L NewSELL17841090.154857525
2022-05-23Glen BurkhardtSELL112480.79
2021-11-19Glen BurkhardtSELL57662.37
2021-08-18Clay ThorpBUY100003
2021-05-20Glen BurkhardtSELL38113.293811
2020-12-03Edmund HarriganBUY60004.126000
2020-11-24Clay ThorpBUY50003.6 
2020-11-23Glen BurkhardtSELL34973.453497
2019-07-01Clay ThorpSELL290814
2019-06-18Clay ThorpSELL40014
2018-12-17Nancy J HutsonBUY10004.46
2018-12-13Jonathan P MowBUY10003.69
2018-12-11Michael YorkBUY15003.88
2018-12-10Jonathan P MowBUY30003.87
2018-12-07John P SharpBUY50003.84
2018-12-04Clay ThorpBUY40003.13
2018-10-22Linda TuftsBUY200005
2018-10-22Venture Advisors Iii HatterasBUY3000005

4. Summary

4.1. Key Performance Indicators

The key performance indicators of PhaseBio Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.301-0.493+64%-0.228-24%-0.120-60%-0.112-63%
Book Value Growth---0.128-0.324+154%-0.920+620%0.024-624%0.024-624%
Book Value Per Share---2.355-1.821-23%-0.159-93%-0.224-91%-0.211-91%
Book Value Per Share Growth---0.128-0.324+154%-0.920+620%0.024-624%0.024-624%
Current Ratio--0.4691.632-71%4.459-89%5.807-92%5.750-92%
Debt To Asset Ratio--6.2963.532+78%1.133+456%1.906+230%1.835+243%
Debt To Equity Ratio----0%5.840-100%1.362-100%1.332-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.334-0.516+54%-0.559+67%-0.3340%-0.326-2%
Eps Growth---0.3310.544-161%0.003-11888%0.092-462%0.092-462%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---80.120-69.719-13%-0.694-99%-22.640-72%-21.561-73%
Operating Margin---79.563-69.042-13%-0.649-99%-22.180-72%-21.124-73%
Operating Ratio--122.69293.460+31%0.759+16063%32.298+280%30.760+299%
Pb Ratio-0.025+90%-0.255-1.344+428%11.100-102%4.031-106%3.839-107%
Pe Ratio-0.177+90%-1.795-3.894+117%-6.312+252%-13.635+660%-12.986+623%
Peg Ratio--5.41515.693-65%14.222-62%-287.711+5413%-287.711+5413%
Price Per Share0.059-917%0.6001.910-69%3.513-83%3.280-82%3.124-81%
Price To Total Gains Ratio-0.196+90%-1.994-4.262+114%-3.800+91%-10.962+450%-10.962+450%
Profit Growth---33.147-198.828+500%0.281-11888%-35.321+7%-35.321+7%
Quick Ratio--0.3161.326-76%3.771-92%5.340-94%5.086-94%
Return On Assets---0.7520.000-4375652%-0.398-47%-0.204-73%-0.301-60%
Return On Equity----0%-2.2570%-0.5710%-0.7280%
Revenue Growth--0.43815.419-97%1.000-56%5.095-91%5.095-91%
Total Gains Per Share---0.301-0.493+64%-0.228-24%-0.120-60%-0.112-63%
Total Gains Per Share Growth---0.3760.700-154%-0.091-76%-1.356+260%-1.356+260%
Usd Book Value---117398000.000-90789000.000-23%-7903500.000-93%-11144700.000-91%-10500428.571-91%
Usd Book Value Change Per Share---0.301-0.493+64%-0.228-24%-0.120-60%-0.112-63%
Usd Book Value Per Share---2.355-1.821-23%-0.159-93%-0.224-91%-0.211-91%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.334-0.516+54%-0.559+67%-0.3340%-0.326-2%
Usd Price Per Share0.059-917%0.6001.910-69%3.513-83%3.280-82%3.124-81%
Usd Profit---16665000.0007024982.250-337%-27888750.000+67%-9734503.550-42%-9710003.381-42%
Usd Revenue--208000.000-2500542.250+1302%2584500.000-92%184241.550+13%175468.143+19%
Usd Total Gains Per Share---0.301-0.493+64%-0.228-24%-0.120-60%-0.112-63%
 EOD+2 -3MRQTTM+13 -17YOY+10 -215Y+7 -2410Y+7 -24

4.2. Fundamental Score

Let's check the fundamental score of PhaseBio Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.177
Price to Book Ratio (EOD)Between0-1-0.025
Net Profit Margin (MRQ)Greater than0-80.120
Operating Margin (MRQ)Greater than0-79.563
Quick Ratio (MRQ)Greater than10.316
Current Ratio (MRQ)Greater than10.469
Debt to Asset Ratio (MRQ)Less than16.296
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.752
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of PhaseBio Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.519
Ma 20Greater thanMa 500.086
Ma 50Greater thanMa 1000.255
Ma 100Greater thanMa 2000.683
OpenGreater thanClose0.060
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-06-302021-09-302021-12-312022-03-312022-06-30
Net Working Capital  72,326-28,54243,784-22,88320,901-15,0205,881-18,996-13,115



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets22,166
Total Liabilities139,564
Total Stockholder Equity-117,398
 As reported
Total Liabilities 139,564
Total Stockholder Equity+ -117,398
Total Assets = 22,166

Assets

Total Assets22,166
Total Current Assets11,564
Long-term Assets11,564
Total Current Assets
Cash And Cash Equivalents 7,804
Other Current Assets 3,760
Total Current Assets  (as reported)11,564
Total Current Assets  (calculated)11,564
+/-0
Long-term Assets
Property Plant Equipment 10,544
Other Assets 58
Long-term Assets  (as reported)10,602
Long-term Assets  (calculated)10,602
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities24,679
Long-term Liabilities114,885
Total Stockholder Equity-117,398
Total Current Liabilities
Short-term Debt 4,503
Short Long Term Debt 4,073
Accounts payable 6,320
Other Current Liabilities 12,456
Total Current Liabilities  (as reported)24,679
Total Current Liabilities  (calculated)27,352
+/- 2,673
Long-term Liabilities
Capital Lease Obligations 1,299
Other Liabilities 114,016
Long-term Liabilities  (as reported)114,885
Long-term Liabilities  (calculated)115,315
+/- 430
Total Stockholder Equity
Common Stock50
Retained Earnings -419,600
Other Stockholders Equity 302,152
Total Stockholder Equity (as reported)-117,398
Total Stockholder Equity (calculated)-117,398
+/-0
Other
Capital Stock50
Cash and Short Term Investments 7,804
Common Stock Shares Outstanding 49,183
Current Deferred Revenue1,400
Liabilities and Stockholders Equity 22,166
Net Debt -2,432
Net Invested Capital -113,325
Net Tangible Assets -117,398
Net Working Capital -13,115
Short Long Term Debt Total 5,372



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-31
> Total Assets 
4,117
14,099
14,099
9,889
29,601
27,488
63,026
56,386
97,438
86,203
82,494
76,858
70,810
58,207
50,357
100,821
100,637
77,725
60,540
38,664
22,166
22,16638,66460,54077,725100,637100,82150,35758,20770,81076,85882,49486,20397,43856,38663,02627,48829,6019,88914,09914,0994,117
   > Total Current Assets 
3,884
13,746
13,746
8,952
28,664
24,968
62,628
54,075
94,897
83,369
78,823
72,541
63,741
49,948
40,149
88,157
88,500
65,241
48,784
27,569
11,564
11,56427,56948,78465,24188,50088,15740,14949,94863,74172,54178,82383,36994,89754,07562,62824,96828,6648,95213,74613,7463,884
       Cash And Cash Equivalents 
3,715
13,406
13,406
8,734
28,446
24,341
61,031
51,894
90,342
81,771
74,025
59,441
53,025
39,353
28,122
76,963
64,456
56,357
41,800
18,688
7,804
7,80418,68841,80056,35764,45676,96328,12239,35353,02559,44174,02581,77190,34251,89461,03124,34128,4468,73413,40613,4063,715
       Net Receivables 
0
0
0
0
0
411
233
670
1,180
583
1,233
896
0
0
57
0
18,400
0
0
0
0
000018,400057008961,2335831,18067023341100000
       Other Current Assets 
169
0
340
0
218
216
1,364
1,511
3,375
1,015
3,565
12,204
10,716
10,595
12,027
11,194
5,644
8,884
6,984
8,881
3,760
3,7608,8816,9848,8845,64411,19412,02710,59510,71612,2043,5651,0153,3751,5111,36421621803400169
   > Long-term Assets 
0
0
353
0
937
2,520
398
2,311
2,541
2,834
3,671
4,317
7,069
8,259
10,208
12,664
12,137
12,484
11,756
11,095
10,602
10,60211,09511,75612,48412,13712,66410,2088,2597,0694,3173,6712,8342,5412,3113982,520937035300
       Property Plant Equipment 
182
302
302
276
276
251
355
2,279
2,509
2,802
3,639
4,285
7,012
8,202
10,151
12,607
12,080
12,427
11,699
11,038
10,544
10,54411,03811,69912,42712,08012,60710,1518,2027,0124,2853,6392,8022,5092,279355251276276302302182
       Long-term Assets Other 
0
0
51
0
661
2,269
43
32
32
32
32
32
57
57
57
57
57
57
57
57
58
5857575757575757573232323232432,26966105100
> Total Liabilities 
1,732
20,225
111,515
25,930
9,247
143,662
12,099
12,304
15,829
15,399
22,516
23,372
44,417
53,855
75,559
92,410
119,812
128,054
153,574
141,059
139,564
139,564141,059153,574128,054119,81292,41075,55953,85544,41723,37222,51615,39915,82912,30412,099143,6629,24725,930111,51520,2251,732
   > Total Current Liabilities 
844
17,595
17,595
23,300
5,117
7,688
4,577
3,797
5,746
5,962
8,479
7,495
17,802
11,370
14,960
16,668
16,174
21,457
27,883
21,688
24,679
24,67921,68827,88321,45716,17416,66814,96011,37017,8027,4958,4795,9625,7463,7974,5777,6885,11723,30017,59517,595844
       Short-term Debt 
0
761
761
2,860
2,860
3,125
0
423
1,265
1,990
2,378
3,686
5,015
5,341
5,355
5,838
5,860
5,884
5,413
5,875
4,503
4,5035,8755,4135,8845,8605,8385,3555,3415,0153,6862,3781,9901,26542303,1252,8602,8607617610
       Short Long Term Debt 
0
761
761
2,860
2,860
3,125
0
423
1,265
1,990
2,378
3,686
5,015
5,341
5,355
5,370
5,384
5,399
5,413
5,425
4,073
4,0735,4255,4135,3995,3845,3705,3555,3415,0153,6862,3781,9901,26542303,1252,8602,8607617610
       Accounts payable 
433
430
430
569
569
1,576
1,806
2,058
3,047
1,659
2,921
1,918
6,967
2,124
3,674
5,898
2,958
8,521
12,570
6,778
6,320
6,3206,77812,5708,5212,9585,8983,6742,1246,9671,9182,9211,6593,0472,0581,8061,576569569430430433
       Other Current Liabilities 
411
3,028
17,165
3,345
4,548
6,112
2,771
1,316
1,434
2,313
3,180
1,891
5,820
3,905
5,931
4,932
5,932
5,638
8,353
7,441
12,456
12,4567,4418,3535,6385,9324,9325,9313,9055,8201,8913,1802,3131,4341,3162,7716,1124,5483,34517,1653,028411
   > Long-term Liabilities 
0
0
93,920
0
4,130
135,974
7,522
8,507
10,083
9,437
14,037
15,877
26,615
42,485
60,599
75,742
103,638
106,597
125,691
119,371
114,885
114,885119,371125,691106,597103,63875,74260,59942,48526,61515,87714,0379,43710,0838,5077,522135,9744,130093,92000
       Long term Debt Total 
0
0
0
0
0
4,375
7,500
6,841
8,429
7,740
12,326
11,058
9,768
8,117
6,773
5,425
4,073
2,718
0
0
0
0002,7184,0735,4256,7738,1179,76811,05812,3267,7408,4296,8417,5004,37500000
       Capital Lease Obligations Min Short Term Debt
0
-761
-761
-2,860
-2,860
-3,125
0
1,505
599
-174
-605
-1,977
-2,817
-3,223
-3,348
-3,942
-4,078
-4,217
-3,865
-4,456
-3,204
-3,204-4,456-3,865-4,217-4,078-3,942-3,348-3,223-2,817-1,977-605-1745991,5050-3,125-2,860-2,860-761-7610
       Warrants
0
0
0
0
0
125,609
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000125,60900000
       Long-term Liabilities Other 
0
0
0
0
0
5,990
0
1,666
56
120
203
295
388
2,144
559
2,057
692
9,842
794
0
0
007949,8426922,0575592,144388295203120561,66605,99000000
       Deferred Long Term Liability 
0
0
0
610
610
2,218
22
0
0
0
0
3,086
14,686
32,224
51,719
68,260
89,329
94,037
0
0
0
00094,03789,32968,26051,71932,22414,6863,0860000222,218610610000
> Total Stockholder Equity
2,385
-97,416
-97,416
-97,416
20,354
-116,174
50,927
44,082
81,609
70,804
59,978
53,486
26,393
4,352
-25,202
8,411
-19,175
-50,329
-93,034
-102,395
-117,398
-117,398-102,395-93,034-50,329-19,1758,411-25,2024,35226,39353,48659,97870,80481,60944,08250,927-116,17420,354-97,416-97,416-97,4162,385
   Common Stock
1
9
1
9
15
1
25
25
29
29
29
29
29
29
29
48
48
48
48
49
50
5049484848482929292929292925251159191
   Retained Earnings Total Equity000-348,684-316,760-288,081-260,723-230,348-205,205-177,100-162,200-150,827-139,436-130,204-122,911-118,04300000
   Accumulated Other Comprehensive Income 0000000-1,784-2,070-2,013-1,959-1,909-1,859-1,816-1,785-1,727-1,6990-1,64500
   Capital Surplus 
0
0
0
0
0
1,892
173,837
174,285
221,040
221,626
222,131
230,544
231,593
234,695
235,516
296,468
297,561
298,331
0
0
0
000298,331297,561296,468235,516234,695231,593230,544222,131221,626221,040174,285173,8371,89200000
   Treasury Stock000-24-24-24-24-24-24-24-24-24-24-24-24-24-240-240-24
   Other Stockholders Equity 
0
0
3,293
0
132,180
3,595
175,598
176,077
222,875
223,511
224,066
232,533
233,639
236,455
235,492
296,444
297,537
298,307
298,712
300,491
302,152
302,152300,491298,712298,307297,537296,444235,492236,455233,639232,533224,066223,511222,875176,077175,5983,595132,18003,29300



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue11
Cost of Revenue--
Gross Profit-11
 
Operating Income (+$)
Gross Profit-
Operating Expense-118
Operating Income-107,362-118
 
Operating Expense (+$)
Research Development102
Selling General Administrative16
Selling And Marketing Expenses-
Operating Expense118118
 
Net Interest Income (+$)
Interest Income14
Interest Expense-1
Net Interest Income-93313
 
Pretax Income (+$)
Operating Income-107,362
Net Interest Income-933
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-129-214,595
EBIT - interestExpense = -131
-129
-130
Interest Expense1
Earnings Before Interest and Taxes (ebit)-130-129
Earnings Before Interest and Taxes (ebitda)1,663
 
After tax Income (+$)
Income Before Tax-129
Tax Provision-1,600
Net Income From Continuing Ops-131,071-1,729
Net Income-131
Net Income Applicable To Common Shares-131,071
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net107,233933
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
TOELY.PINK
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TOELY.PINK.

TOELY.PINK Daily Candlestick Chart
AAUKF.OTCQX
3 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of AAUKF.OTCQX.

AAUKF.OTCQX Daily Candlestick Chart
WSRD.TO
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WSRD.TO.

WSRD.TO Daily Candlestick Chart
ZWA.TO
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZWA.TO.

ZWA.TO Daily Candlestick Chart
MMTW.INDX
6 minutes ago

I found you a MACD Bullish Hidden Divergence on the daily chart of MMTW.INDX.

MMTW.INDX Daily Candlestick Chart
MMTH.INDX
6 minutes ago

I found you a Golden Cross on the daily chart of MMTH.INDX.

MMTH.INDX Daily Candlestick Chart
PSEI.INDX
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PSEI.INDX.

PSEI.INDX Daily Candlestick Chart
ZWC.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZWC.TO.

ZWC.TO Daily Candlestick Chart
ZWB.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZWB.TO.

ZWB.TO Daily Candlestick Chart
ZLC.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZLC.TO.

ZLC.TO Daily Candlestick Chart
ZLU.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZLU.TO.

ZLU.TO Daily Candlestick Chart
ZLB.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZLB.TO.

ZLB.TO Daily Candlestick Chart
ZDV.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZDV.TO.

ZDV.TO Daily Candlestick Chart
XST.TO
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XST.TO.

XST.TO Daily Candlestick Chart
XFN.TO
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XFN.TO.

XFN.TO Daily Candlestick Chart
XAW.TO
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XAW.TO.

XAW.TO Daily Candlestick Chart
VXC.TO
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VXC.TO.

VXC.TO Daily Candlestick Chart
TRP.TO
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TRP.TO.

TRP.TO Daily Candlestick Chart
TGED.TO
9 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TGED.TO.

TGED.TO Daily Candlestick Chart
WINDLAS.BSE
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WINDLAS.BSE.

WINDLAS.BSE Daily Candlestick Chart
MBB.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MBB.XETRA.

MBB.XETRA Daily Candlestick Chart
VIKASWSP.BSE
15 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VIKASWSP.BSE.

VIKASWSP.BSE Daily Candlestick Chart
H5E.XETRA
15 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of H5E.XETRA.

H5E.XETRA Daily Candlestick Chart
SYBR.XETRA
16 minutes ago

I found you a Death Cross on the daily chart of SYBR.XETRA.

SYBR.XETRA Daily Candlestick Chart
REP.XETRA
16 minutes ago

I found you a Golden Cross on the daily chart of REP.XETRA.

REP.XETRA Daily Candlestick Chart